Truist raised the firm’s price target on Tenet Healthcare (THC) to $190 from $180 and keeps a Buy rating on the shares. The firm is bullish after the company’s “strong” Q3 results featuring top and bottom-line beats that were fueled by strong Hospital volumes and brisk revenue per case growth, the analyst tells investors in a research note. The initial FY25 commentary was also solid, with attractive trends expected to more than offset some normalizing factors, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $177 from $168 at Cantor Fitzgerald
- Tenet Healthcare price target raised to $217 from $197 at UBS
- Tenet Healthcare price target raised to $183 from $174 at RBC Capital
- Tenet Healthcare Reports Strong Q3 Results and Raises Outlook
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz